Neoadjuvant Immunotherapy With Durvalumab and Tremelimumab for Bladder Cancer Patients Ineligible for Cisplatin
Clinical trial NCT03234153 · TERMINATED
Trial details
- NCT number
- NCT03234153
- Sponsor
- Insel Gruppe AG, University Hospital Bern
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-07-15
- Primary completion
- 2019-11-08
- Enrollment
- 6
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.